Randomized Phase II Study of Concurrent and Sequential Rituximab and CHOP Chemotherapy in Untreated Indolent B-cell Lymphoma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2006 Apr 25

PMID 16630123

Citations 9

Authors

Michinori Ogura

Yasuo Morishima

Yoshitoyo Kagami

Takashi Watanabe

Kuniaki Itoh

Tadahiko Igarashi

Tomomitsu Hotta

Tomohiro Kinoshita

Yasuo Ohashi

Shigeo Mori

Takashi Terauchi

Kensei Tobinai

Affiliations

Soon will be listed here.

Abstract

CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. We performed a randomized phase II study to explore a more promising schedule in untreated, advanced indolent B-NHL. Patients were randomized to receive either six courses of CHOP concurrently with rituximab (Arm C), or six courses of CHOP followed by six courses of weekly rituximab (Arm S). A total of 69 patients received the concurrent (n=34) or sequential (n=35) regimen. Overall response rate (ORR) in Arm C was 94% (95% confidence interval [CI], 79 to 99), including a 66% complete response (CR) compared with 97% (95% CI, 85-100), including a 68% CR in Arm S. Patients in Arm C experienced more grade 4 neutropenia (85%versus 70%) and experienced more grade 3 or greater non-hematological toxicities (21%versus 12%). Both arms were tolerated well. With a median follow-up of 28.2 months, the median progression-free survival (PFS) time was 34.2 months in Arm C, and was not reached in Arm S. R-CHOP is highly effective in untreated indolent B-NHL, either concurrent or in a sequential combination. Both combination schedules deserve further investigation.

Citing Articles

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

Zhu R, Lu D, Chu Y, Chai A, Green M, Zhang N AAPS J. 2017; 19(3):669-681.

PMID: 28224402 DOI: 10.1208/s12248-017-0056-x.

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K Int J Hematol. 2016; 105(4):470-477.

PMID: 27900638 DOI: 10.1007/s12185-016-2146-4.

Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.

Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y Int J Hematol. 2016; 104(6):700-708.

PMID: 27714587 DOI: 10.1007/s12185-016-2097-9.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Singh J, Wells G, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald J Cochrane Database Syst Rev. 2011; (2):CD008794.

PMID: 21328309 PMC: 7173749. DOI: 10.1002/14651858.CD008794.pub2.

Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.

Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T Cancer Sci. 2010; 101(12):2579-85.

PMID: 20942866 PMC: 11159922. DOI: 10.1111/j.1349-7006.2010.01703.x.

References

Czuczman M, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L . Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23(4):694-704. DOI: 10.1200/JCO.2005.02.172. View

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Maloney D, Grillo-Lopez A, Bodkin D, White C, Liles T, Royston I . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997; 15(10):3266-74. DOI: 10.1200/JCO.1997.15.10.3266. View

Byrd J, Peterson B, Morrison V, Park K, Jacobson R, Hoke E . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2002; 101(1):6-14. DOI: 10.1182/blood-2002-04-1258. View

Solal-Celigny P . Management of histologically indolent non-Hodgkin's lymphomas. Baillieres Clin Haematol. 1996; 9(4):669-87. DOI: 10.1016/s0950-3536(96)80048-5. View

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K . Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993; 23(4):250-7. View

Hainsworth J, Burris 3rd H, Morrissey L, Litchy S, Scullin Jr D, Bearden 3rd J . Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000; 95(10):3052-6. View

10.

Foran J, Gupta R, Cunningham D, Popescu R, Goldstone A, Sweetenham J . A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000; 109(1):81-8. DOI: 10.1046/j.1365-2141.2000.01965.x. View

11.

Fleming T . One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38(1):143-51. View

12.

Hainsworth J, Litchy S, Burris 3rd H, Scullin Jr D, Corso S, Yardley D . Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002; 20(20):4261-7. DOI: 10.1200/JCO.2002.08.674. View

13.

Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B . Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol. 1994; 5 Suppl 2:67-71. View

14.

McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, Williams M . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16(8):2825-33. DOI: 10.1200/JCO.1998.16.8.2825. View

15.

Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y . Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998; 9(5):527-34. DOI: 10.1023/a:1008265313133. View

16.

Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle.... Blood. 2004; 104(10):3064-71. DOI: 10.1182/blood-2004-04-1323. View

17.

Berger F, Felman P, Sonet A, Salles G, Bastion Y, Bryon P . Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood. 1994; 83(10):2829-35. View

18.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

19.

Hiddemann W, Unterhalt M . Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas. Blood Rev. 1994; 8(4):225-33. DOI: 10.1016/0268-960x(94)90110-4. View

20.

Freedman A, Gribben J, Neuberg D, Mauch P, Soiffer R, Anderson K . High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996; 88(7):2780-6. View